BioCentury
ARTICLE | Finance

Sickle syndicate

Why Cydan's backers joined firm in its second rare disease spinout

April 18, 2016 7:00 AM UTC

Orphan drug accelerator Cydan Development Inc. gathered enough preclinical data to convince its investor syndicate that sickle cell candidate IMR-687 is an asset worth building a company around.

Cydan debuted in 2013 to identify, de-risk and spin out rare disease programs from academia, not-for-profits and industry (see BioCentury, April 15, 2013)...